Lindbrook Capital, LLC Agenus Inc Transaction History

Lindbrook Capital, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	SELL	$0.63 - $1.14 $33,095 - $59,887	-52,533 Reduced 100.0%	2 $0
Q3 2023 Oct 25, 2023	BUY	$1.12 - $1.88 $16,434 - $27,587	14,674 Added 38.76%	52,535 $59,000
Q2 2023 Jul 28, 2023	BUY	$1.31 - $2.04 $47,160 - $73,440	36,000 Added 1934.44%	37,861 $60,000
Q1 2023 Apr 26, 2023	SELL	$1.45 - $2.95 $1.95 Million - $3.97 Million	-1,344,331 Reduced 99.86%	1,861 $2,000
Q4 2022 Jan 24, 2023	BUY	$2.02 - $3.25 $2.72 Million - $4.37 Million	1,344,953 Added 108551.49%	1,346,192 $0
Q3 2022 Nov 10, 2022	BUY	$1.96 - $3.14 $507 - $813	259 Added 26.43%	1,239 $3,000
Q2 2022 Aug 01, 2022	SELL	$1.3 - $2.64 $373 - $757	-287 Reduced 22.65%	980 $2,000
Q1 2022 Apr 21, 2022	BUY	$2.35 - $3.47 $2,977 - $4,396	1,267 New	1,267 $3,000
Q4 2021 Jan 18, 2022	SELL	$2.92 - $5.74 $23,360 - $45,920	-8,000 Closed	0 $0
Q3 2021 Nov 05, 2021	BUY	$4.98 - $6.63 $39,840 - $53,040	8,000 New	8,000 $42,000
Q4 2020 Jan 27, 2021	SELL	$3.17 - $4.49 $20,605 - $29,185	-6,500 Closed	0 $0
Q3 2020 Nov 03, 2020	BUY	$2.98 - $5.2 $1,490 - $2,600	500 Added 8.33%	6,500 $26,000
Q2 2020 Jul 27, 2020	BUY	$2.29 - $4.24 $13,740 - $25,440	6,000 New	6,000 $24,000

2.07M

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.